Study Data Show Abbott's CardioMEMSDevice Can Improve Care for More Patients with Heart Failure

Abbott today announced results of the landmark GUIDE-HF clinical trial, a 1,000 patient randomized study designed to assess the benefits of the CardioMEMS HF System in people living with NYHA Class II, III and IV heart failure. Data adjusted for the impact of COVID-19 show a strong reduction in a composite endpoint of heart failure hospitalizations, emergency visits and death in a broad range of patients, suggesting new benefits from the CardioMEMS device.